June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
T-cell and cytokine investigations in an experimental model of retinal ganglion cell loss
Author Affiliations & Notes
  • Sandra Kuehn
    Experimental Eye Resch Inst, Ruhr University Bochum, Bochum, Germany
  • Rozina Noristani
    Experimental Eye Resch Inst, Ruhr University Bochum, Bochum, Germany
  • Mathias Kuehn
    Experimental Eye Resch Inst, Ruhr University Bochum, Bochum, Germany
  • Burkhard Dick
    Experimental Eye Resch Inst, Ruhr University Bochum, Bochum, Germany
  • Stephanie Joachim
    Experimental Eye Resch Inst, Ruhr University Bochum, Bochum, Germany
  • Footnotes
    Commercial Relationships Sandra Kuehn, None; Rozina Noristani, None; Mathias Kuehn, None; Burkhard Dick, None; Stephanie Joachim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2025. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandra Kuehn, Rozina Noristani, Mathias Kuehn, Burkhard Dick, Stephanie Joachim; T-cell and cytokine investigations in an experimental model of retinal ganglion cell loss. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2025.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: In the last years immune activities of destructive nature were detected in retina of glaucoma patients. Evidence of T-cell activities was noted in blood of patients. These immune cells can act via pro-apoptotic cytokines, which are great contributors in the mechanism of cell death. In order to investigate the role of T-cells in a glaucomatous model we detected cells and we looked at the cytokines to define the T-cell status.

Methods: Rats were immunized with optic nerve homogenate antigen (ONA, n=6) or NaCl (Co, n=6). Over a 4 week period the intraocular pressure (IOP) was measured in ONA and Co group. 14 days post immunization (p.i.) the CD3+ T-cell number was measured in the retina with a Cyflow FACS and the groups were compared to a shame immunized group (Naïve: n=6). At 28 days cryo-cross sections of the eyes were stained with Brn-3a in combination with CD3, TNF-α or FasL. The serum TNF-α concentration was measured with an ELISA Kit. Groups were compared with student t-test.

Results: IOP remained constant in Co and ONA (p=0.4) group throughout the project. 28 days p.i. the retinal ganglion cell (RGC) density of the immunized group decreased compared with Co (Co: 5±3.3/section; ONA: 3.6±2.5/section, p=0.001). In comparison with the Naïve group the retinal CD3+ T-cell number increased significantly in the ONA group (p=0.04) after 14 days. 28 days p.i. no T-cells and hardly any TNF-α signal were detected in the retinae of Co and ONA. In the serum of both groups the TNF-α concentration is extremely low, with no differences between the groups. For this reason the concentration wasn't detectable with the ELISA at the point of time 4 weeks p.i.. The FasL signal was quantifiable in all retina layers, but no significant differences between the groups were noted (Co: 15.6±9.2; ONA 9.7±4.6, p=0.4) at 4 weeks.

Conclusions: In the ONA group the RGC loss increases significantly without an elevation of the IOP after 28 days. While the ONA animals displayed a slight T-cell infiltration in the retina at 14 days, no T-cell activities were detectable at 28 days. The T-cell effect seems to be an early event, because the 28 days hardly any T-cell dependent immune activities were noted: no CD3+ signal in the retina, no sign for retinal and systemic TNF-α, and no changes in retinal FasL formation. The antigen ONA seems to have a time dependent influence to the immune mechanism of T-cells.

Keywords: 695 retinal degenerations: cell biology • 529 flow cytometry • 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×